$36.50/share cashStrategic acquisitionHealthcare & Life SciencesCompleted
Viatris completes $36.50-a-share takeover of Pacira BioSciences
Viatris has completed its acquisition of non-opioid pain specialist Pacira BioSciences after a $36.50-per-share cash tender offer. About 66.46% of shares were tendered, and Pacira was then merged into a Viatris subsidiary. The deal was first announced on Oct. 8, 2026.
Why it matters: Viatris says the deal gives it a leadership position in non-opioid pain management as it builds out its U.S. innovative medicines business.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.
See what you get →